跳轉至內容
Merck
  • Discovery of novel SERCA inhibitors by virtual screening of a large compound library.

Discovery of novel SERCA inhibitors by virtual screening of a large compound library.

European journal of medicinal chemistry (2011-03-01)
Christopher Elam, Michael Lape, Joel Deye, Jodie Zultowsky, David T Stanton, Stefan Paula
摘要

Two screening protocols based on recursive partitioning and computational ligand docking methodologies, respectively, were employed for virtual screens of a compound library with 345,000 entries for novel inhibitors of the enzyme sarco/endoplasmic reticulum calcium ATPase (SERCA), a potential target for cancer chemotherapy. A total of 72 compounds that were predicted to be potential inhibitors of SERCA were tested in bioassays and 17 displayed inhibitory potencies at concentrations below 100 μM. The majority of these inhibitors were composed of two phenyl rings tethered to each other by a short link of one to three atoms. Putative interactions between SERCA and the inhibitors were identified by inspection of docking-predicted poses and some of the structural features required for effective SERCA inhibition were determined by analysis of the classification pattern employed by the recursive partitioning models.

材料
產品編號
品牌
產品描述

Supelco
双酚 A, ≥99%
Sigma-Aldrich
叔丁基氢醌, 97%
Sigma-Aldrich
双酚 A, 97%
Sigma-Aldrich
对苯二酚, ReagentPlus®, ≥99%
Sigma-Aldrich
2,5-二甲基苯酚, ≥99%
Sigma-Aldrich
2,5-二叔丁基氢醌, 99%
Sigma-Aldrich
2,6-二叔丁基-4-甲氧基苯酚, 97%
Sigma-Aldrich
4-肉桂苯酚, 99%
Sigma-Aldrich
对苯二酚, ReagentPlus®, 99%
Sigma-Aldrich
2,5-二甲苯酚, ≥99%, FG
Sigma-Aldrich
2,2-双(4-羟基-3,5-二甲基苯基)丙烷, 98%
Sigma-Aldrich
N -Boc-4-羟基苯胺, 97%
Sigma-Aldrich
2,5-二叔丁基苯胺, 99%
Sigma-Aldrich
对苯二酚, meets USP testing specifications
Sigma-Aldrich
4-三苯代甲基苯酚, 97%